Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 11:57 PM
Ignite Modification Date: 2025-12-24 @ 11:57 PM
NCT ID: NCT04770051
Eligibility Criteria: Inclusion Criteria: 1. Appropriate ICD shock for ventricular tachycardia (VT) after at least one catheter ablation of VT procedure, OR appropriate ICD shock for VT but not a candidate for catheter ablation of VT (i.e. patients with presence polymorphic VT or ventricular fibrillation, LV thrombus, VT arising from an inaccessible myocardial location). 2. Presence of structural heart disease as defined as EF ≤ 50%, presence of ventricular scar as detected by imaging modalities or electroanatomic mapping, hypertrophic cardiomyopathy, cardiac sarcoidosis, or arrhythmogenic right ventricular cardiomyopathy. 3. Patient is taking at least one anti-arrhythmic drug or has documented intolerance or toxicity to at least one anti-arrhythmic drug. 4. Age greater than 18 years old. 5. Able and willing to comply with all pre- and follow-up testing and requirements. 6. Provision of signed informed consent and stated willingness to comply with all study procedures for duration of the study. Exclusion Criteria: 1. Active ongoing cardiac ischemia as assessed by: EKG, cardiac enzymes, symptoms, coronary angiography with evidence of significant epicardial coronary stenosis (\>70%), or stress testing. (Note: positive troponin assay due to ICD shocks is not an exclusion criterion). 2. Any medical or non-medical condition likely to prevent completion of trial. 3. Contraindication to cardiac sympathetic denervation (i.e. single-lung ventilation, severe pulmonary disease, or severe pulmonary hypertension) or previous cardiac sympathetic denervation procedure. 4. Left ventricular assist device or status post orthotopic heart transplantation 5. Severe thrombocytopenia (platelets \< 50,000) or coagulopathy (INR \> 2.0) that is not due to medications or a reversible cause. 6. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal). 7. Unable or unwilling to comply with protocol requirements. 8. NYHA class IV heart failure symptoms. 9. Known channelopathy such as long QT syndrome and catecholaminergic polymorphic VT. 10. Presentation with slow VT (VT rate \< 150 bpm).
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 80 Years
Study: NCT04770051
Study Brief:
Protocol Section: NCT04770051